Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Meiji Seika To Develop Antidepressant Mirtazapine For Fibromyalgia

This article was originally published in PharmAsia News

Executive Summary

Meiji Seika will develop antidepressant Reflex (mirtazapine) for fibromyalgia in Japan

Meiji Seika will develop antidepressant Reflex (mirtazapine) for fibromyalgia in Japan.

The company plans to start an early Phase II trial in July, aiming for a new drug application in 2015. There are an estimated 2 million fibromyalgia patients in Japan, and no drugs have been approved for the disease. Worldwide, several drugs have been indicated for the central nervous system disease, including Lyrica (pregabalin) from Pfizer/Eisai, Toledomin (milnacipran) from Asahi Kasei/Janssen Pharma, Cymbalta (duloxetine) from Eli Lilly/Shionogi. Pfizer and Eisai are conducting trials on pregabalin for patients with fibromyalgia in Japan. Mirtazapine is also marketed as Remeron in Japan by Schering Plough. (Click here for more - Japanese language)

"Meiji Seika Expands Antidepressant Reflex To Treat Bibromyalgia" - CB News (6/17/2010)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC075138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By